Enterprise Value
3.88M
Cash
44.43M
Avg Qtr Burn
-20.71M
Short % of Float
2.64%
Insider Ownership
11.80%
Institutional Own.
43.86%
Qtr Updated
09/30/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zokinvy™ (lonafarnib) Details Progeroid laminopathies, Progeria, Hutchinson-Gilford progeria syndrome | Approved Quarterly sales | |
Lonafarnib Details Liver disease, Infectious disease, Hepatitis D | Phase 3 Update | |
Avexitide (GLP-1 Antagonist) Details Metabolic disorder, Congenital Hyperinsulinism | Phase 3 Update | |
Avexitide (GLP-1 Antagonist) Details Post-Bariatric Hypoglycemia, Metabolic disorder, Rare diseases | Phase 3 Update | |
Peginterferon Lambda + Lonafarnib Details Infectious disease, Hepatitis D | Phase 2 Update | |
Failed Discontinued | ||
Peginterferon Lambda (Lambda) Details Infectious disease, Hepatitis D | Failed Discontinued |